Shenqi(SH:600613) Quan Jing Wang·2025-09-19 10:15Core Insights - The company participated in a collective reception day and mid-year performance briefing on September 19, 2023, aimed at enhancing communication with investors [1] - The company is focusing on evidence-based research in oncology and cardiovascular treatment, exploring clinical value and conducting post-market evaluations [1] - The company is developing new compounds based on existing products and is engaged in research for new indications through innovation and research system development [1] Product Development and Market Strategy - The company is working on the development of improved new drugs and upgrading existing products based on its product reserves [1] - Collaborations with research institutions are being pursued to advance the development of chemical drugs, traditional Chinese medicine, and health products [1] - The company’s subsidiary, Guizhou Guangdeli Pharmaceutical Co., Ltd., exports products such as gelatin capsules and plant-based capsules to various regions, including North America and Europe, starting in 2024 [2] Export and Revenue Insights - In the first half of 2025, the subsidiary achieved export revenue of 1,833,947.39 yuan, accounting for 0.19% of the company's total revenue [2] - Due to tariff issues, the subsidiary plans to suspend exports to the United States starting in 2025 [2] - Currently, there are no additional overseas market expansion plans beyond existing operations [2]